AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome-Reference-Cited by-同舟云学术

AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome

Published:2022-05-27 Issue:1 Volume:27 Page:636-641
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Assaf Nada¹^ORCID,Lefebvre Christine²,Raggueneau Victoria³,Guignedoux Geoffroy⁴,Marceau-Renaut Alice⁵,Chevalier Simon²,Tondeur Sylvie²,Bories Dominique⁶,Benramdane Riad⁴,Rousselot Philippe⁷,Terré Christine⁸

Affiliation:

1. Department of Pathology and Laboratory Medicine, Cytogenetics division, American University of Beirut Medical Center, Beirut, Lebanon

2. Laboratoire d’Hématologie Biologique, Centre Hospitalier Universitaire de Grenoble Alpes (CHUGA), La Tronche, France

3. Department of Laboratory Medicine, Hematology, Centre Hospitalier de Versailles, Le Chesnay, France

4. Laboratoire d’Hématologie, Centre Hospitalier René Dubos Pontoise, Pontoise, France

5. University of Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020–UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France

6. Department of Molecular Onco-Hematology Henri Mondor Hospital (APHP-UPEC), Créteil, France

7. Department of Hematology, Centre Hospitalier de Versailles, France & University Paris-Saclay, UMR1184, Le Chesnay, France

8. Department of Laboratory Medicine, Hemato-Oncologic Cytogenetics, Centre Hospitalier de Versailles, Le Chesnay, France

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2022.2078027

Reference20 articles.

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Vol. 2. International agency for research on cancer Lyon, France; 2008.

2. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

3. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

4. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH);Current Research in Translational Medicine;2023-10

2. Azacitidine/carboplatin/paclitaxel;Reactions Weekly;2023-06-24